Ventyx Biosciences Inc(VTYX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.5 | Insider Own | 12.9% | Shs Outstand | 71.3M | Perf Week | - |
| Market Cap | 1.00B | Forward P/E | - | EPS next Y | -27.03% | Insider Trans | -0.64% | Shs Float | 62.5M | Perf Month | 0.43% |
| Enterprise Value | 0.82B | PEG | - | EPS next Q | -0.4 | Inst Own | 75.92% | Short Float | 7.78% | Perf Quarter | 61.1% |
| Income | -0.11B | P/S | - | EPS this Y | 24.84% | Inst Trans | - | Short Ratio | 1.33 | Perf Half Y | 488.24% |
| Sales | 0.00B | P/B | 5.22 | EPS next 5Y | 11.47% | ROA | -41.6% | Short Interest | 4.86M | Perf YTD | 55.04% |
| Book/sh | 2.68 | P/C | 5.22 | EPS past 3/5Y | -5.26% -87.13% | ROE | -45.35% | 52W High | -44% ($25.00) | Perf Year | 872.22% |
| Cash/sh | 2.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.25% | 52W Low | 1687.99% ($0.78) | Perf 3Y | -69.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 36.65% | Gross Margin | - | Volatility(W/M) | 0.14% 0.22% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.86 | EPS Q/Q | 35.81% | Profit Margin | - | RSI (14) | 72.63 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.86 | Sales Q/Q | - | SMA20 | 0.3% ($13.96) | Beta | 1.28 | Target Price | $14 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 11000000 | SMA50 | 10.1% ($12.72) | Rel Volume | 0 | Prev Close | $14 |
| Employees | 82 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 28.7% - | SMA200 | 120.8% ($6.34) | Avg Volume(3M) | 3.66M | Price | $14 |
| IPO | 2021/10/21 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
💊 Develops oral small-molecule drugs for autoimmune, inflammatory, and neurodegenerative diseases. A leading developer of NLRP3 inhibitors. Acquired by Eli Lilly (January 2026).
Over the past 1 year, roughly in the middle
44% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
VTYX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +24.8% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -70.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 75.9%.
Tap to view numbers
It ranks #152 of 598 in the industry
Based on market cap of $1B.
VSTM#151 Verastem Inc $1B PER - VTYX#152 Ventyx Biosciences Inc $1B PER - 
SVRA#152 Savara Inc $992M PER - 
ANRO#153 Alto Neuroscience Inc $987M PER - 
MLTX#154 MoonLake Immunotherapeutics $981M PER - 
FAQ
What kind of company is VTYX?
VTYX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VTYX?
The market cap of VTYX is approximately $1.0B, ranking 2,541 within its sector.
What is the 52-week high and low for VTYX?
VTYX has recorded a 52-week high of $25.00 and a low of $0.78.
